Drugs / J5-OMP Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01164514 | Nov 2011 → Feb 2013 | bacterial infectious disease with sepsis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | J5-OMP Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01164514 ↗ |
| Modality | Vaccine | “A vaccine composed of the detoxified LPS (dLPS) from E. coli O111:B4 (J5 mutant) non-covalently complexed to group B meningococcal outer membrane protein (OMP).” PMID 26514420 ↗ Oct 2015 |
| Route | Intramuscular | “J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.” NCT01164514 ↗ |